Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27935667 | 0.78 | PDE4A (0.38) | CA2CA4MAPTTSHRAPOBEC3A | |
| SCHEMBL22711494 | 0.78 | CA2 (0.35) | CA2CA4MAPTTSHRAPOBEC3A | |
| SCHEMBL321000 | 0.73 | — | — | |
| SCHEMBL10614301 | 0.72 | — | — | |
| SCHEMBL23413045 | 0.71 | KDM4E (0.40) | MAPTTSHRHSD17B10ALOX15NPC1 | |
| SCHEMBL13933259 | 0.70 | — | — | |
| SCHEMBL12086920 | 0.69 | MAPT (0.47) | MAPTTSHRNCOA1NCOA3HSD17B10 | |
| SCHEMBL16065202 | 0.68 | — | — | |
| SCHEMBL28272412 | 0.67 | — | — | |
| SCHEMBL31398758 | 0.67 | CA2 (0.44) | CA2CA4CA1CA6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655685-B | Thiophene derivative and use thereof | 藤本株式会社 | 2023-11-17 | — | — | CN | disclosed |
| EP-3744719-B1 | THIOPHENE DERIVATIVE AND USE THEREOF | FUJIMOTO CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-11299485-B2 | Thiophene derivative and use thereof | FUJIMOTO CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-20210061795-A1 | THIOPHENE DERIVATIVE AND USE THEREOF | FUJIMOTO CO., LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| EP-3744719-A1 | THIOPHENE DERIVATIVE AND USE THEREOF | Fujimoto Co., Ltd. (JP) | 2020-12-02 | — | — | EP | disclosed |
| CN-111655685-A | Thiophene derivative and use thereof | 藤本株式会社 | 2020-09-11 | — | — | CN | disclosed |
| EP-1551818-B1 | THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7368472-B2 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2008-05-06 | — | — | US | disclosed |
| EP-1578740-B1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | LUNDBECK & CO AS H (DK) | 2007-03-21 | — | — | EP | disclosed |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2006-01-19 | — | — | US | disclosed |
| EP-1578740-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. Lundbeck A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058739-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061795-A1 | THIOPHENE DERIVATIVE AND USE THEREOF | TNF, TPMT, CD47 | CA2 3420/4885CA4 2854/4885MAPT 3905/4885 |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | PMP22, GRIN2B, AVPR1B | CA2 1547/4885CA4 1377/4885MAPT 392/4885 |
| US-11299485-B2 | Thiophene derivative and use thereof | TNF, TPMT, CD47 | CA2 3420/4885CA4 2854/4885MAPT 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.